{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T06:06:50Z","timestamp":1783922810184,"version":"3.55.0"},"reference-count":110,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.bcp.2026.118102","type":"journal-article","created":{"date-parts":[[2026,5,24]],"date-time":"2026-05-24T13:51:17Z","timestamp":1779630677000},"page":"118102","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"P1","title":["Maurice Hilleman, Merck\u2019s monument for mankind, a reappraisal"],"prefix":"10.1016","volume":"251","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2985-8890","authenticated-orcid":false,"given":"Erik De","family":"Clercq","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.bcp.2026.118102_b0005","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1073\/pnas.64.1.67","article-title":"Induction of interferon by preparations of synthetic single-stranded RNA","volume":"64","author":"Baron","year":"1969","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bcp.2026.118102_b0010","series-title":"Vaccinated: one Man\u2019s Quest to Defeat the World\u2019s Deadliest Diseases","author":"Offit","year":"2007"},{"issue":"19","key":"10.1016\/j.bcp.2026.118102_b0015","doi-asserted-by":"crossref","first-page":"5178","DOI":"10.1021\/ja01504a038","article-title":"Studies on the antiviral agent helenine. Purification and evidence for ribonucleoprotein nature","volume":"82","author":"Lewis","year":"1960","journal-title":"J Am Chem Soc"},{"issue":"2","key":"10.1016\/j.bcp.2026.118102_b0020","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1084\/jem.123.2.213","article-title":"An antiviral substance from Penicillium funiculosum. IV. Inquiry into the mechanism by which helenine exerts its antiviral effect","volume":"123","author":"Shope","year":"1966","journal-title":"J. Exp. Med."},{"issue":"4","key":"10.1016\/j.bcp.2026.118102_b0025","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1084\/jem.123.4.577","article-title":"An antiviral substance from Penicillium funiculosum. V. Induction of interferon by helenine","volume":"123","author":"Rytel","year":"1966","journal-title":"J. Exp. Med."},{"issue":"2","key":"10.1016\/j.bcp.2026.118102_b0030","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1073\/pnas.58.2.782","article-title":"Inducers of interferon and host resistance. I. Double-stranded RNA from extracts of Penicillium funiculosum","volume":"58","author":"Lampson","year":"1967","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"3","key":"10.1016\/j.bcp.2026.118102_b0035","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1073\/pnas.58.3.1004","article-title":"Inducers of interferon and host resistance. II. Multistranded synthetic polynucleotide complexes","volume":"58","author":"Field","year":"1967","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"4","key":"10.1016\/j.bcp.2026.118102_b0040","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1073\/pnas.58.4.1719","article-title":"Inducers of interferon and host resistance. 3. Double-stranded RNA from reovirus type 3 virions (reo 3-RNA)","volume":"58","author":"Tytell","year":"1967","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"5","key":"10.1016\/j.bcp.2026.118102_b0045","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1073\/pnas.58.5.2102","article-title":"Inducers of interferon and host resistance, IV. Double-stranded replicative form RNA (MS2-Ff-RNA) from E. coli infected with MS2 coliphage","volume":"58","author":"Field","year":"1967","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.bcp.2026.118102_b0050","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1073\/pnas.61.1.340","article-title":"Inducers of interferon and host resistance, V. In Vitro Studies","volume":"61","author":"Field","year":"1968","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"10.1016\/j.bcp.2026.118102_b0055","doi-asserted-by":"crossref","first-page":"784","DOI":"10.3181\/00379727-132-34309","article-title":"Inducers of interferon and host resistance. VII. Antiviral efficacy of double-stranded RNA of natural origin","volume":"132","author":"Nemes","year":"1969","journal-title":"Proc. Soc. Exp. Biol. Med."},{"issue":"4","key":"10.1016\/j.bcp.2026.118102_b0060","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.3181\/00379727-137-35754","article-title":"In vitro safety assessment of double-stranded polynucleotides poly I:C and Mu-9","volume":"137","author":"Baugh","year":"1971","journal-title":"Proc. Soc. Exp. Biol. Med."},{"issue":"2","key":"10.1016\/j.bcp.2026.118102_b0065","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1093\/infdis\/121.2.196","article-title":"Prospects for the use of double-stranded ribonucleic acid (poly I:C) inducers in man","volume":"121","author":"Hilleman","year":"1970","journal-title":"J Infect Dis"},{"issue":"1","key":"10.1016\/j.bcp.2026.118102_b0070","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1001\/archinte.1970.00310070111010","article-title":"Double-stranded RNAs (poly I:C) in the prevention of viral infections","volume":"126","author":"Hilleman","year":"1970","journal-title":"Arch. Intern. Med."},{"issue":"3","key":"10.1016\/j.bcp.2026.118102_b0075","doi-asserted-by":"crossref","first-page":"911","DOI":"10.3181\/00379727-135-35169","article-title":"Relationship of molecular size of rIn:rCn (poly I:C) to induction of interferon and host resistance","volume":"135","author":"Lampson","year":"1970","journal-title":"Proc. Soc. Exp. Biol. Med."},{"issue":"3","key":"10.1016\/j.bcp.2026.118102_b0080","doi-asserted-by":"crossref","first-page":"917","DOI":"10.3181\/00379727-135-35170","article-title":"Influence of size of individual homopolynucleotides on the physical and biological properties of complexed rIn:rCn (poly I:C)","volume":"135","author":"Tytell","year":"1970","journal-title":"Proc. Soc. Exp. Biol. Med."},{"key":"10.1016\/j.bcp.2026.118102_b0085","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1126\/science.173.3993.260","article-title":"Antiviral activity of polyribocytidylic acid in cells primed with polyriboinosinic acid","volume":"173","author":"De Clercq","year":"1971","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.bcp.2026.118102_b0090","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.3181\/00379727-136-35454","article-title":"Induction of interferon in human subjects by poly I:C","volume":"136","author":"Field","year":"1971","journal-title":"Proc. Soc. Exp. Biol. Med."},{"issue":"4","key":"10.1016\/j.bcp.2026.118102_b0095","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.3181\/00379727-139-36310","article-title":"Antigenicity of double-stranded ribonucleic acids including poly I:C","volume":"139","author":"Field","year":"1972","journal-title":"Proc. Soc. Exp. Biol. Med."},{"issue":"2","key":"10.1016\/j.bcp.2026.118102_b0100","doi-asserted-by":"crossref","first-page":"710","DOI":"10.3181\/00379727-140-36537","article-title":"Cellular control of interferon production and release after treatment with poly I:C inducer","volume":"140","author":"Field","year":"1972","journal-title":"Proc. Soc. Exp. Biol. Med."},{"issue":"3","key":"10.1016\/j.bcp.2026.118102_b0105","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.3181\/00379727-141-36934","article-title":"The effect of altering the size of poly C on the toxicity and antigenicity of poly I:C","volume":"141","author":"Lampson","year":"1972","journal-title":"Proc. Soc. Exp. Biol. Med."},{"issue":"4","key":"10.1016\/j.bcp.2026.118102_b0110","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1089\/jir.1981.1.539","article-title":"Poly I:C\/poly-L-lysine: potent inducer of interferons in primates","volume":"1","author":"Lampson","year":"1981","journal-title":"J. Interferon Res."},{"issue":"4","key":"10.1016\/j.bcp.2026.118102_b0115","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1073\/pnas.63.4.1102","article-title":"The pathogenesis of autoimmunity in New Zealand mice, I. Induction of Antinucleic Acid Antibodies by Polyinosinic-Polycytidylic Acid","volume":"63","author":"Steinberg","year":"1969","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"10.1016\/j.bcp.2026.118102_b0120","doi-asserted-by":"crossref","first-page":"476","DOI":"10.3181\/00379727-148-38565","article-title":"Safety assessment of poly I:C in NZB\/NZW mice (38565)","volume":"148","author":"Mendlowski","year":"1975","journal-title":"Proc. Soc. Exp. Biol. Med."},{"key":"10.1016\/j.bcp.2026.118102_b0125","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/285542a0","article-title":"Isolation and structure of a human fibroblast interferon gene","volume":"285","author":"Derynck","year":"1980","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2026.118102_b0130","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/287193a0","article-title":"Expression of human fibroblast interferon gene in Escherichia coli","volume":"287","author":"Derynck","year":"1980","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.bcp.2026.118102_b0135","doi-asserted-by":"crossref","first-page":"159","DOI":"10.3181\/00379727-56-14632P","article-title":"Immunologic relations of the psittacosis-lymphogranuloma group of viral agents","volume":"56","author":"Hilleman","year":"1944","journal-title":"Proc. Soc. Exp. Biol. Med."},{"issue":"2","key":"10.1016\/j.bcp.2026.118102_b0140","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1093\/infdis\/76.2.96","article-title":"Immunological studies on the psittacosis-lymphogranuloma group of viral agents","volume":"76","author":"Hilleman","year":"1945","journal-title":"J Infect Dis"},{"issue":"3","key":"10.1016\/j.bcp.2026.118102_b0145","doi-asserted-by":"crossref","first-page":"259","DOI":"10.4049\/jimmunol.53.3.259","article-title":"Studies on lymphogranuloma venereum complement-fixing antigens; enhancement by phenol or boiling","volume":"53","author":"Nigg","year":"1946","journal-title":"J. Immunol."},{"key":"10.1016\/j.bcp.2026.118102_b0150","doi-asserted-by":"crossref","first-page":"201","DOI":"10.4049\/jimmunol.53.2.201","article-title":"Studies on lymphogranuloma venereum complement-fixing antigens the solubility in ether of an active fraction","volume":"53","author":"Hilleman","year":"1946","journal-title":"J. Immunol."},{"issue":"4","key":"10.1016\/j.bcp.2026.118102_b0155","doi-asserted-by":"crossref","first-page":"349","DOI":"10.4049\/jimmunol.59.4.349","article-title":"Studies on lymphogranuloma venereum complement-fixing antigens; fractionation with organic solvents of antigens of the psittacosis-lymphogranuloma venereum group","volume":"59","author":"Hilleman","year":"1948","journal-title":"J. Immunol."},{"issue":"3","key":"10.1016\/j.bcp.2026.118102_b0160","doi-asserted-by":"crossref","first-page":"829","DOI":"10.3181\/00379727-75-18361","article-title":"Antigenic pattern of strains of influenza a and B","volume":"75","author":"Hilleman","year":"1950","journal-title":"Proc. Soc. Exp. Biol. Med."},{"issue":"1","key":"10.1016\/j.bcp.2026.118102_b0165","doi-asserted-by":"crossref","first-page":"208","DOI":"10.3181\/00379727-78-19023","article-title":"System for measuring and designating antigenic components of influenza viruses with analyses of recently isolated strains","volume":"78","author":"Hilleman","year":"1951","journal-title":"Proc. Soc. Exp. Biol. Med."},{"issue":"3","key":"10.1016\/j.bcp.2026.118102_b0170","doi-asserted-by":"crossref","first-page":"343","DOI":"10.4049\/jimmunol.69.3.343","article-title":"Comparison of the antigenic patterns of influenza a virus strains determined by in ovo neutralization and hemagglutination-inhibition","volume":"69","author":"Hilleman","year":"1952","journal-title":"J. Immunol."},{"key":"10.1016\/j.bcp.2026.118102_b0175","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1146\/annurev.mi.08.100154.001523","article-title":"Antigenic variation of influenza viruses","volume":"8","author":"Hilleman","year":"1954","journal-title":"Annu. Rev. Microbiol."},{"issue":"3","key":"10.1016\/j.bcp.2026.118102_b0180","doi-asserted-by":"crossref","first-page":"952","DOI":"10.3181\/00379727-123-31647","article-title":"Influenza B in the spring of 1965","volume":"123","author":"Mascoli","year":"1966","journal-title":"Proc. Soc. Exp. Biol. Med."},{"issue":"2","key":"10.1016\/j.bcp.2026.118102_b0185","doi-asserted-by":"crossref","first-page":"377","DOI":"10.3181\/00379727-92-22484","article-title":"Prevention of acute respiratory illness in recruits by adenovirus (RI-APC-ARD) vaccine","volume":"92","author":"Hilleman","year":"1956","journal-title":"Proc. Soc. Exp. Biol. Med."},{"issue":"8","key":"10.1016\/j.bcp.2026.118102_b0190","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/j.1749-6632.1957.tb46049.x","article-title":"Epidemiology of adenovirus respiratory infections in military recruit populations","volume":"67","author":"Hilleman","year":"1957","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"7","key":"10.1016\/j.bcp.2026.118102_b0195","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1172\/JCI103502","article-title":"Acute respiratory illness in volunteers following intramuscular administration of live adenovirus","volume":"36","author":"Hilleman","year":"1957","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.bcp.2026.118102_b0200","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1001\/archinte.1958.00260130061005","article-title":"Adenovirus vaccine; development, field evaluation, and appraisal of the need for vaccination in military and civilian populations","volume":"101","author":"Hilleman","year":"1958","journal-title":"A.M.A. Arch. Intern. Med."},{"issue":"4","key":"10.1016\/j.bcp.2026.118102_b0205","doi-asserted-by":"crossref","first-page":"299","DOI":"10.4049\/jimmunol.80.4.299","article-title":"Antibody response in volunteers to adenovirus vaccine and correlation of antibody with immunity","volume":"80","author":"Hilleman","year":"1958","journal-title":"J. Immunol."},{"key":"10.1016\/j.bcp.2026.118102_b0210","doi-asserted-by":"crossref","first-page":"20","DOI":"10.4049\/jimmunol.84.1.20","article-title":"A guinea pig potency test for adenovirus vaccine","volume":"84","author":"Binn","year":"1960","journal-title":"J. Immunol."},{"key":"10.1016\/j.bcp.2026.118102_b0215","doi-asserted-by":"crossref","first-page":"717","DOI":"10.3181\/00379727-106-26452","article-title":"Studies of acute respiratory illnesses caused by respiratory syncytial virus. 1. Laboratory findings in 109 cases","volume":"106","author":"Hamparian","year":"1961","journal-title":"Proc. Soc. Exp. Biol. Med."},{"key":"10.1016\/j.bcp.2026.118102_b0220","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1056\/NEJM196106082642301","article-title":"Studies of acute respiratory illnesses caused by respiratory syncytial virus. 2. Epidemiology and assessment of importance","volume":"264","author":"McClelland","year":"1961","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcp.2026.118102_b0225","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1056\/NEJM196106082642302","article-title":"Studies of acute respiratory illnesses caused by respiratory syncytial virus. 3. Clinical and laboratory findings","volume":"264","author":"Reilly","year":"1961","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcp.2026.118102_b0230","unstructured":"R.E. Weibel, J. Stokes, Jr., M.B. Leagus, C.C. Mascoli, A.A. Tytell, A.F. Woodhour, P.P. Vella, M.R. Hilleman, Respiratory virus vaccines. VII. Field evaluation of respiratory syncytial, parainfluenza 1, 2, 3, and Mycoplasma pneumoniae vaccines, 1965 to 1966, Am Rev Respir Dis 96(4) (1967) 724-39."},{"issue":"2","key":"10.1016\/j.bcp.2026.118102_b0235","doi-asserted-by":"crossref","first-page":"272","DOI":"10.3181\/00379727-160-40433","article-title":"Further investigations of live respiratory syncytial virus vaccine administered parenterally","volume":"160","author":"Buynak","year":"1979","journal-title":"Proc. Soc. Exp. Biol. Med."},{"issue":"2","key":"10.1016\/j.bcp.2026.118102_b0240","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3181\/00379727-86-21073","article-title":"Propagation in tissue cultures of cytopathogenic agents from patients with measles","volume":"86","author":"Enders","year":"1954","journal-title":"Proc. Soc. Exp. Biol. Med."},{"key":"10.1016\/j.bcp.2026.118102_b0245","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1056\/NEJM196008042630504","article-title":"Use of living attenuated measles-virus vaccine in early infancy","volume":"263","author":"Stokes","year":"1960","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcp.2026.118102_b0250","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1056\/NEJM196107272650403","article-title":"Living attenuated measles-virus vaccine in early infancy. Studies of the Role of Passive Antibody in Immunization","volume":"265","author":"Reilly","year":"1961","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bcp.2026.118102_b0255","doi-asserted-by":"crossref","unstructured":"M.R. Hilleman, J. Stokes, Jr., E.B. Buynak, R. Weibel, R. Halenda, H. Goldner, Studies of live attenuated measles virus vaccine in man. II. Appraisal of efficacy, Am J Public Health Nations Health 52(2)Suppl(Suppl 2) (1962) 44-56.","DOI":"10.2105\/AJPH.52.Suppl_2.44"},{"key":"10.1016\/j.bcp.2026.118102_b0260","doi-asserted-by":"crossref","unstructured":"J. Stokes, Jr., R. Weibel, R. Halenda, C.M. Reilly, M.R. Hilleman, Studies of live attenuated measles virus vaccine in man. I. Clinical aspects, Am J Public Health Nations Health 52(2)Suppl(Suppl 2) (1962) 29-43.","DOI":"10.2105\/AJPH.52.Suppl_2.29"},{"key":"10.1016\/j.bcp.2026.118102_b0265","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1056\/NEJM196208022670503","article-title":"Persistent immunity following Enders live, attenuated measles-virus vaccine given with human immune globulin","volume":"267","author":"Stokes","year":"1962","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcp.2026.118102_b0270","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1056\/NEJM196401232700403","article-title":"Durable immunity two years after administration of Enders's live measles-virus vaccine with immune globulin","volume":"270","author":"Weibel","year":"1964","journal-title":"N. Engl. J. Med."},{"issue":"5\u20136","key":"10.1016\/j.bcp.2026.118102_b0275","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0264-410X(01)00384-X","article-title":"Current overview of the pathogenesis and prophylaxis of measles with focus on practical implications","volume":"20","author":"Hilleman","year":"2001","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.bcp.2026.118102_b0280","doi-asserted-by":"crossref","first-page":"768","DOI":"10.3181\/00379727-123-31599","article-title":"Live attenuated mumps virus vaccine. 1. vaccine development","volume":"123","author":"Buynak","year":"1966","journal-title":"Proc. Soc. Exp. Biol. Med."},{"issue":"5","key":"10.1016\/j.bcp.2026.118102_b0285","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1056\/NEJM196702022760501","article-title":"Live, attenuated mumps-virus vaccine. 3. Clinical and serologic aspects in a field evaluation","volume":"276","author":"Weibel","year":"1967","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.bcp.2026.118102_b0290","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1056\/NEJM196702022760502","article-title":"Live, attenuated mumps-virus vaccine. IV. protective efficacy as measured in a field evaluation","volume":"276","author":"Hilleman","year":"1967","journal-title":"N. Engl. J. Med."},{"issue":"13","key":"10.1016\/j.bcp.2026.118102_b0295","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1001\/jama.1967.03130130021005","article-title":"Vaccination of adults with live attenuated mumps virus vaccine","volume":"201","author":"Davidson","year":"1967","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.bcp.2026.118102_b0300","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1001\/jama.1968.03140010016003","article-title":"Jeryl Lynn strain live attenuated mumps virus vaccine. Durability of Immunity following Administration","volume":"203","author":"Weibel","year":"1968","journal-title":"Jama"},{"issue":"5","key":"10.1016\/j.bcp.2026.118102_b0305","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1542\/peds.40.5.798","article-title":"Experiences with Jeryl Lynn strain live attenuated mumps virus vaccine in a pediatric outpatient clinic","volume":"40","author":"Young","year":"1967","journal-title":"Pediatrics"},{"issue":"5","key":"10.1016\/j.bcp.2026.118102_b0310","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1056\/NEJM196802012780501","article-title":"Live, attenuated mumps-virus vaccine","volume":"278","author":"Hilleman","year":"1968","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.bcp.2026.118102_b0315","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1542\/peds.45.5.821","article-title":"Persistence of immunity four years following Jeryl Lynn strain live mumps virus vaccine","volume":"45","author":"Weibel","year":"1970","journal-title":"Pediatrics"},{"issue":"6","key":"10.1016\/j.bcp.2026.118102_b0320","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1002\/cpt196676752","article-title":"Advances in control of viral infections by nonspecific measures and by vaccines, with special reference to live mumps and rubella virus vaccines","volume":"7","author":"Hilleman","year":"1966","journal-title":"Clin. Pharmacol. Ther."},{"issue":"3","key":"10.1016\/j.bcp.2026.118102_b0325","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1001\/jama.1968.03140160005002","article-title":"Live attenuated rubella virus vaccines prepared in duck embryo cell culture. I. Development and clinical testing","volume":"204","author":"Buynak","year":"1968","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.bcp.2026.118102_b0330","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1056\/NEJM196808082790607","article-title":"Live, attenuated rubella-virus vaccine","volume":"279","author":"Hilleman","year":"1968","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.bcp.2026.118102_b0335","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1001\/jama.1968.03140340024005","article-title":"Live attenuated rubella virus vaccines prepared in duck embryo cell culture. II. Clinical tests in families and in an institution","volume":"205","author":"Weibel","year":"1968","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.bcp.2026.118102_b0340","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1001\/archpedi.1969.02100040188005","article-title":"Rubella virus vaccine (HPV-77-DE 5). Antigenic and Protective Efficacy in a Community Trial","volume":"118","author":"McCollum","year":"1969","journal-title":"Am J Dis Child"},{"issue":"6","key":"10.1016\/j.bcp.2026.118102_b0345","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1001\/jama.1971.03180320027005","article-title":"Combined live rubella-mumps virus vaccine. Findings in Clinical-Laboratory Studies","volume":"216","author":"Weibel","year":"1971","journal-title":"Jama"},{"issue":"4","key":"10.1016\/j.bcp.2026.118102_b0350","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/S0022-3476(71)80306-2","article-title":"Combined live measles-rubella virus vaccine. Findings in Clinical Laboratory Studies","volume":"79","author":"Villarejos","year":"1971","journal-title":"J Pediatr"},{"issue":"7","key":"10.1016\/j.bcp.2026.118102_b0355","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1136\/adc.48.7.532","article-title":"Combined live measles-mumps virus vaccine","volume":"48","author":"Weibel","year":"1973","journal-title":"Arch. Dis. Child."},{"issue":"12","key":"10.1016\/j.bcp.2026.118102_b0360","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1001\/jama.1969.03150250089009","article-title":"Combined live measles, mumps, and rubella virus vaccines","volume":"207","author":"Buynak","year":"1969","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.bcp.2026.118102_b0365","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1001\/jama.1971.03190140033006","article-title":"Trivalent combined measles-mumps-rubella vaccine. Findings in Clinical-Laboratory Studies","volume":"218","author":"Stokes","year":"1971","journal-title":"Jama"},{"issue":"3","key":"10.1016\/j.bcp.2026.118102_b0370","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1542\/peds.49.3.334","article-title":"Measurement of immunity following live mumps (5 years), measles (3 years), and rubella (2 and one-half years) virus vaccines","volume":"49","author":"Weibel","year":"1972","journal-title":"Pediatrics"},{"issue":"3","key":"10.1016\/j.bcp.2026.118102_b0375","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1542\/peds.51.3.467","article-title":"Persistence of immunity following monovalent and combined live measles, mumps, and rubella virus vaccines","volume":"51","author":"Weibel","year":"1973","journal-title":"Pediatrics"},{"issue":"3","key":"10.1016\/j.bcp.2026.118102_b0380","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1542\/peds.56.3.380","article-title":"Long-term follow-up for immunity after monovalent or combined live measles, mumps, and rubella virus vaccines","volume":"56","author":"Weibel","year":"1975","journal-title":"Pediatrics"},{"issue":"1","key":"10.1016\/j.bcp.2026.118102_b0385","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1542\/peds.61.1.5","article-title":"Persistence of antibody after administration of monovalent and combined live attenuated measles, mumps, and rubella virus vaccines","volume":"61","author":"Weibel","year":"1978","journal-title":"Pediatrics"},{"issue":"2","key":"10.1016\/j.bcp.2026.118102_b0390","doi-asserted-by":"crossref","first-page":"260","DOI":"10.3181\/00379727-165-40967","article-title":"Persistence of antibody in human subjects for 7 to 10 years following administration of combined live attenuated measles, mumps, and rubella virus vaccines","volume":"165","author":"Weibel","year":"1980","journal-title":"Proc. Soc. Exp. Biol. Med."},{"issue":"2","key":"10.1016\/j.bcp.2026.118102_b0395","doi-asserted-by":"crossref","first-page":"323","DOI":"10.3181\/00379727-165-40979","article-title":"Clinical and laboratory studies of combined live measles, mumps, and rubella vaccines using the RA 27\/3 rubella virus","volume":"165","author":"Weibel","year":"1980","journal-title":"Proc. Soc. Exp. Biol. Med."},{"issue":"5 Suppl","key":"10.1016\/j.bcp.2026.118102_b0400","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/nm0598supp-507","article-title":"Six decades of vaccine development - a personal history","volume":"4","author":"Hilleman","year":"1998","journal-title":"Nat. Med."},{"issue":"15","key":"10.1016\/j.bcp.2026.118102_b0405","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1016\/S0264-410X(99)00434-X","article-title":"Vaccines in historic evolution and perspective: a narrative of vaccine discoveries","volume":"18","author":"Hilleman","year":"2000","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.bcp.2026.118102_b0410","doi-asserted-by":"crossref","first-page":"276","DOI":"10.3181\/00379727-142-37005","article-title":"Recovery of hepatitis agents in the marmoset from human cases occurring in Costa Rica","volume":"142","author":"Mascoli","year":"1973","journal-title":"Proc. Soc. Exp. Biol. Med."},{"issue":"1","key":"10.1016\/j.bcp.2026.118102_b0415","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/00000441-197507000-00013","article-title":"Biophysical and biochemical properties of CR326 human hepatitis a virus","volume":"270","author":"Provost","year":"1975","journal-title":"Am. J. Med. Sci."},{"issue":"2","key":"10.1016\/j.bcp.2026.118102_b0420","doi-asserted-by":"crossref","first-page":"532","DOI":"10.3181\/00379727-148-38578","article-title":"Physical, chemical and morphologic dimensions of human hepatitis a virus strain CR326 (38578)","volume":"148","author":"Provost","year":"1975","journal-title":"Proc. Soc. Exp. Biol. Med."},{"issue":"2","key":"10.1016\/j.bcp.2026.118102_b0425","doi-asserted-by":"crossref","first-page":"201","DOI":"10.3181\/00379727-159-40314","article-title":"An inactivated hepatitis a virus vaccine prepared from infected marmoset liver","volume":"159","author":"Provost","year":"1978","journal-title":"Proc. Soc. Exp. Biol. Med."},{"issue":"2","key":"10.1016\/j.bcp.2026.118102_b0430","doi-asserted-by":"crossref","first-page":"213","DOI":"10.3181\/00379727-160-40422","article-title":"Propagation of human hepatitis a virus in cell culture in vitro","volume":"160","author":"Provost","year":"1979","journal-title":"Proc. Soc. Exp. Biol. Med."},{"issue":"3","key":"10.1016\/j.bcp.2026.118102_b0435","doi-asserted-by":"crossref","first-page":"357","DOI":"10.3181\/00379727-172-41570","article-title":"Studies in chimpanzees of live, attenuated hepatitis a vaccine candidates","volume":"172","author":"Provost","year":"1983","journal-title":"Proc. Soc. Exp. Biol. Med."},{"key":"10.1016\/j.bcp.2026.118102_b0440","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1001\/jama.1965.03080070025007","article-title":"A \u201cnew\u201d antigen in leukemia sera","volume":"191","author":"Blumberg","year":"1965","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.bcp.2026.118102_b0445","doi-asserted-by":"crossref","first-page":"924","DOI":"10.7326\/0003-4819-66-5-924","article-title":"A serum antigen (Australia antigen) in Down's syndrome, leukemia, and hepatitis","volume":"66","author":"Blumberg","year":"1967","journal-title":"Ann. Intern. Med."},{"issue":"2","key":"10.1016\/j.bcp.2026.118102_b0450","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1097\/00000441-197509000-00025","article-title":"Purified and inactivated human hepatitis B vaccine: progress report","volume":"270","author":"Hilleman","year":"1975","journal-title":"Am. J. Med. Sci."},{"issue":"4","key":"10.1016\/j.bcp.2026.118102_b0455","doi-asserted-by":"crossref","first-page":"694","DOI":"10.3181\/00379727-151-39288","article-title":"Development and chimpanzee testing of a vaccine against human hepatitis B","volume":"151","author":"Buynak","year":"1976","journal-title":"Proc. Soc. Exp. Biol. Med."},{"issue":"26","key":"10.1016\/j.bcp.2026.118102_b0460","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.1001\/jama.1976.03260520026017","article-title":"Vaccine against human hepatitis B","volume":"235","author":"Buynak","year":"1976","journal-title":"JAMA"},{"issue":"Suppl 1","key":"10.1016\/j.bcp.2026.118102_b0465","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0163-4453(83)96465-4","article-title":"The preparation and safety of hepatitis B vaccine","volume":"7","author":"Hilleman","year":"1983","journal-title":"J. Infect."},{"issue":"15\u201316","key":"10.1016\/j.bcp.2026.118102_b0470","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1016\/S0264-410X(00)00364-9","article-title":"Overview of the pathogenesis, prophylaxis and therapeusis of viral hepatitis B, with focus on reduction to practical applications","volume":"19","author":"Hilleman","year":"2001","journal-title":"Vaccine"},{"issue":"5947","key":"10.1016\/j.bcp.2026.118102_b0475","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/307178a0","article-title":"Human hepatitis B vaccine from recombinant yeast","volume":"307","author":"McAleer","year":"1984","journal-title":"Nature"},{"issue":"7892","key":"10.1016\/j.bcp.2026.118102_b0480","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/S0140-6736(74)90144-5","article-title":"Live vaccine used to prevent the spread of varicella in children in hospital","volume":"2","author":"Takahashi","year":"1974","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.bcp.2026.118102_b0485","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/S0022-3476(82)80506-4","article-title":"Live attenuated varicella vaccine: immunization of healthy children with the OKA strain","volume":"100","author":"Arbeter","year":"1982","journal-title":"J. Pediatr."},{"issue":"22","key":"10.1016\/j.bcp.2026.118102_b0490","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1056\/NEJM198405313102201","article-title":"Live attenuated varicella virus vaccine. Efficacy Trial in Healthy Children","volume":"310","author":"Weibel","year":"1984","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.bcp.2026.118102_b0495","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1038\/nm1195-1126","article-title":"Whether and when an AIDS vaccine?","volume":"1","author":"Hilleman","year":"1995","journal-title":"Nat. Med."},{"issue":"1996","key":"10.1016\/j.bcp.2026.118102_b0500","first-page":"161","article-title":"Strategies for the achievement of prophylactic vaccination against HIV","volume":"48","author":"Hilleman","year":"1971","journal-title":"Antibiot. Chemother."},{"issue":"8","key":"10.1016\/j.bcp.2026.118102_b0505","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/S0264-410X(97)00272-7","article-title":"A simplified vaccinologists' vaccinology and the pursuit of a vaccine against AIDS","volume":"16","author":"Hilleman","year":"1998","journal-title":"Vaccine"},{"issue":"9\u201310","key":"10.1016\/j.bcp.2026.118102_b0510","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/S0264-410X(98)00345-4","article-title":"The business of science and the science of business in the quest for an AIDS vaccine","volume":"17","author":"Hilleman","year":"1999","journal-title":"Vaccine"},{"issue":"1\u20132","key":"10.1016\/j.bcp.2026.118102_b0515","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S1386-6532(00)00132-3","article-title":"Overview of vaccinology with special reference to papillomavirus vaccines","volume":"19","author":"Hilleman","year":"2000","journal-title":"J. Clin. Virol."},{"issue":"16","key":"10.1016\/j.bcp.2026.118102_b0520","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.2217\/fvl-2023-0196","article-title":"Management of viral infections: vaccines or antivirals","volume":"18","author":"De Clercq","year":"2023","journal-title":"Futur. Virol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118102_b0525","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2217\/fvl-2022-0169","article-title":"Plain language summary of Pfizer-BioNTech BNT162b2 vaccine protection against COVID-19 and its safety in participants 12- to 15-years-old","volume":"18","author":"Frenck","year":"2023","journal-title":"Futur. Virol."},{"issue":"10","key":"10.1016\/j.bcp.2026.118102_b0530","doi-asserted-by":"crossref","first-page":"615","DOI":"10.2217\/fvl-2023-0020","article-title":"Plain language summary of a clinical trial evaluating mRNA-1273, Moderna\u2019s mRNA-based COVID-19 vaccine, in children 6 through 11 years of age","volume":"18","author":"Creech","year":"2023","journal-title":"Futur. Virol."},{"key":"10.1016\/j.bcp.2026.118102_b0535","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.bcp.2017.11.023","article-title":"Role of tenofovir alafenamide (TAF) in the treatment and prophylaxis of HIV and HBV infections","volume":"153","author":"De Clercq","year":"2018","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2026.118102_b0540","doi-asserted-by":"crossref","DOI":"10.3390\/v17070959","article-title":"The meandrous route of rilpivirine in the search for the miraculous drug to treat HIV infections","author":"De Clercq","year":"2025","journal-title":"Viruses"},{"key":"10.1016\/j.bcp.2026.118102_b0545","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2025.117125","article-title":"Lenacapavir: a capsid inhibitor for HIV-1 treatment and prevention","volume":"240","author":"De Clercq","year":"2025","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2026.118102_b0550","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.antiviral.2017.02.014","article-title":"Current therapy for chronic hepatitis C: the role of direct-acting antivirals","volume":"142","author":"Li","year":"2017","journal-title":"Antiviral Res."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226004375?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226004375?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T05:26:15Z","timestamp":1783920375000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295226004375"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":110,"alternative-id":["S0006295226004375"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2026.118102","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Maurice Hilleman, Merck\u2019s monument for mankind, a reappraisal","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2026.118102","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118102"}}